Processa Pharmaceuticals, Inc. (PCSA)
Automate Your Wheel Strategy on PCSA
With Tiblio's Option Bot, you can configure your own wheel strategy including PCSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PCSA
- Rev/Share 800.8979
- Book/Share 392.2672
- PB 0.0008
- Debt/Equity 0.0042
- CurrentRatio 3.4483
- ROIC -2.1247
- MktCap 15900246.0
- FreeCF/Share -697.1434
- PFCF -1.4649
- PE -0.0004
- Debt/Assets 0.0031
- DivYield 0
- ROE -3.4235
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Processa Pharmaceuticals Provides Portfolio and Business Update
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Continue enrolling patients in Phase 2 study of PCS6422 Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates on its product pipeline, upcoming milestones and business activities.
Read More
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the “Company”), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a public offering of 28,000,000 shares of common stock (or pre-funded warrants in lieu thereof), together with common warrants to purchase up to 28,000,000 shares of common stock at a combined public offering price of $0.25 per share (or pre-funded warrant in lieu thereof) and associated common warrant. The common warrants will have an exercise price of $0.25 per share, are exercisable upon issuance and will expire five years thereafter. …
Read More
About Processa Pharmaceuticals, Inc. (PCSA)
- IPO Date 2014-03-07
- Website https://www.processapharmaceuticals.com
- Industry Biotechnology
- CEO George K. Ng
- Employees 10